MaxCyte (MXCT) Revenue & Revenue Breakdown
MaxCyte Revenue Highlights
Latest Revenue (Y)
$38.63M
Latest Revenue (Q)
$8.16M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
MaxCyte Revenue by Period
MaxCyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $38.63M | -6.44% |
| 2023-12-31 | $41.29M | -6.72% |
| 2022-12-31 | $44.26M | 30.59% |
| 2021-12-31 | $33.89M | 29.52% |
| 2020-12-31 | $26.17M | 21.04% |
| 2019-12-31 | $21.62M | 29.72% |
| 2018-12-31 | $16.67M | 19.18% |
| 2017-12-31 | $13.98M | 13.98% |
| 2016-12-31 | $12.27M | 32.07% |
| 2015-12-31 | $9.29M | 29.67% |
| 2014-12-31 | $7.16M | 5.28% |
| 2013-12-31 | $6.80M | 34.50% |
| 2012-12-31 | $5.06M | - |
MaxCyte generated $38.63M in revenue during NA 2024, up -6.44% compared to the previous quarter, and up 178.66% compared to the same period a year ago.
MaxCyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $8.16M | -21.72% |
| 2024-06-30 | $10.43M | -8.05% |
| 2024-03-31 | $11.34M | -27.60% |
| 2023-12-31 | $15.67M | 95.71% |
| 2023-09-30 | $8.00M | -11.48% |
| 2023-06-30 | $9.04M | 5.44% |
| 2023-03-31 | $8.58M | -30.97% |
| 2022-12-31 | $12.42M | 16.73% |
| 2022-09-30 | $10.64M | 10.77% |
| 2022-06-30 | $9.61M | -17.08% |
| 2022-03-31 | $11.59M | 14.14% |
| 2021-12-31 | $10.15M | 0.13% |
| 2021-09-30 | $10.14M | 42.64% |
| 2021-06-30 | $7.11M | 9.44% |
| 2021-03-31 | $6.49M | -23.72% |
| 2020-12-31 | $8.51M | 25.90% |
| 2020-09-30 | $6.76M | 31.30% |
| 2020-06-30 | $5.15M | -10.30% |
| 2020-03-31 | $5.74M | -13.31% |
| 2019-12-31 | $6.62M | - |
| 2019-09-30 | $6.62M | 58.21% |
| 2019-06-30 | $4.19M | - |
| 2019-03-31 | $4.19M | -14.01% |
| 2018-12-31 | $4.87M | - |
| 2018-09-30 | $4.87M | 40.51% |
| 2018-06-30 | $3.46M | - |
| 2018-03-31 | $3.46M | -10.87% |
| 2017-12-31 | $3.89M | - |
| 2017-09-30 | $3.89M | 25.20% |
| 2017-06-30 | $3.11M | - |
| 2017-03-31 | $3.11M | -8.71% |
| 2016-12-31 | $3.40M | - |
MaxCyte generated $8.16M in revenue during Q3 2024, up -21.72% compared to the previous quarter, and up 90.28% compared to the same period a year ago.
MaxCyte Revenue Breakdown
MaxCyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Product and Service, Other | $1.13M | - | - | - |
| Product | $21.09M | - | - | - |
| Product sales | - | $18.60M | $27.73M | $20.79M |
| Other | - | $897.00K | $1.02M | $784.60K |
MaxCyte's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (94.93%), and Product and Service, Other (5.07%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Service, Other | $710.00K | $416.00K | - | - | - | - | - | - | - | - | - | - | - |
| Product | $15.89M | $5.20M | - | - | - | - | - | - | - | - | - | - | - |
| Product sales | - | - | $5.36M | $8.39M | $5.42M | $4.79M | $7.43M | $6.93M | $6.81M | $6.57M | $7.23M | $5.44M | - |
| Other | - | - | $223.00K | $520.40K | $202.80K | $173.80K | $330.90K | $227.30K | $170.60K | $289.70K | $279.30K | $165.30K | $176.80K |
| Product Sales | - | - | - | - | - | - | - | - | - | - | - | - | $4.04M |
MaxCyte's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (95.72%), and Product and Service, Other (4.28%).
MaxCyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 |
|---|---|
| Non-US | $12.86M |
| UNITED STATES | $25.77M |
MaxCyte's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (66.71%), and Non-US (33.29%).
MaxCyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.72B | $746.27M |
| CNMD | CONMED | $1.31B | $316.70M |
| KIDS | OrthoPediatrics | $204.73M | $52.80M |
| ANIK | Anika Therapeutics | $166.66M | $38.75M |
| SRDX | Surmodics | $126.08M | $29.92M |
| LUNG | Pulmonx | $83.79M | $20.39M |
| NPCE | NeuroPace | $79.91M | $21.06M |
| SGHT | Sight Sciences | $79.87M | $20.16M |
| IRMD | IRadimed | $73.24M | $18.33M |
| CVRX | CVRx | $51.29M | $13.37M |
| MXCT | MaxCyte | $38.63M | $8.16M |
| RPID | Rapid Micro Biosystems | $28.05M | $7.60M |
| OFIX | Orthofix Medical | - | $198.62M |